



ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

Publicly Held Company – CVM No. 2612-3

CNPJ/MF nº 12.104.241/0004-02

NIRE 35.300.493.699

Material Fact

Oncoclínicas do Brasil Serviços Médicos S.A. (ONCO3) (“Company”), in compliance with Article 157, § 4, of Law No. 6,404/76, as amended, and CVM Resolution No. 44/21, and in continuation of the Material Fact disclosed on January 9, 2026, and the Notice to the market disclosed on February 19, 2026, hereby informs its shareholders and the market in general that the Board of Directors, at a meeting held today, unanimously approved the election of Carlos Gil Moreira Ferreira to the position of Chief Executive Officer of the Company on an interim basis until the succession process for Bruno Ferrari is completed.

Bruno Ferrari, Founder and Vice-Chairman of the Company's Board of Directors, today submitted his resignation as Chief Executive Officer, a position he has held since October 19, 2021, leading the organic and inorganic growth process. Bruno Ferrari will continue as Vice-Chairman of the Company's Board of Directors.

Carlos Gil Moreira Ferreira is an oncologist and joined the Company in 2018 as President of Instituto Oncoclínicas and, since 2021, as Medical Director, having collaborated directly in the consolidation of a care model based on high quality, cohesion of the clinical staff, and the pursuit of sustainability in the healthcare system.

The board members expressed their gratitude for Mr. Bruno Ferrari's dedication and contribution during his tenure as Chief Executive Officer of the Company.

São Paulo, March 5th, 2026.

Camille Loyo Faria

Executive Vice President, Finance and Investor Relations